Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
BACKGROUND: Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated.METHODS: CDKN2A mutation carriers that have developed metastatic melanoma and undergone immunotherapy treatments we
